![Presidential_22.10_Powels_Heijden](/var/esmo/storage/images/media/esmo-daily-reporter/images/esmo-congress-2023/live_coverage/22.10.2023/presidential_22.10_powels_heijden/18329807-1-eng-GB/presidential_22.10_powels_heijden_i770.jpg)
Combination therapies with immunotherapy and ADCs prolong overall survival in urothelial carcinoma
Positive outcomes in advanced or metastatic disease reported from EV-302/KEYNOTE-A39 and CheckMate 901 indicate an alternative to first-line chemotherapy for the first time